GlassScriptPhysician profile
Aaron Kobernick
NPI 1306027842
$5,587.13
in general payments reported to CMS, 2019-2025
20 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.32 · 2020: $2,727 · 2021: $108 · 2023: $327 · 2024: $1,035 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704 · Education: $31.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.69 |
| Education | $31.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,885.42 | 2020-2025 | |
| Sanofi Pasteur INC. | $1,353.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $724.61 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $550.03 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $291.35 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $178.44 | 2023-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $141.42 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $128.52 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $63.87 | 2023-2025 | Takhzyro, Eohilia |
| Axsome Therapeutics, INC. | $40.58 | 2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $38.97 | 2024 | Quviviq |
| Biocryst US Sales Co., LLC | $33.20 | 2024 | Orladeyo |
| Harmony Biosciences LLC | $27.86 | 2025 | |
| Blueprint Medicines Corporation | $25.16 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.57 | 2025 | Tezspire |
| Jubilant Hollisterstier LLC | $17.40 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.32 | 2019 | |
| Covis Pharma Gmbh | $16.73 | 2023 | |
| Csl Behring | $14.18 | 2025 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kobernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.